Nisa Investment Advisors LLC cut its stake in Danaher Corporation (NYSE:DHR - Free Report) by 18.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 199,018 shares of the conglomerate's stock after selling 46,521 shares during the period. Nisa Investment Advisors LLC's holdings in Danaher were worth $40,862,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fortis Capital Advisors LLC raised its position in Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares during the period. Fayez Sarofim & Co raised its position in Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after acquiring an additional 50 shares during the period. Coastal Bridge Advisors LLC raised its position in Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after acquiring an additional 50 shares during the period. Perennial Investment Advisors LLC raised its position in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after buying an additional 51 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC lifted its stake in shares of Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after buying an additional 52 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.
Danaher Trading Up 0.1%
Shares of DHR traded up $0.25 during trading on Wednesday, reaching $200.93. 2,050,741 shares of the company traded hands, compared to its average volume of 3,496,423. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The stock has a market cap of $143.80 billion, a PE ratio of 39.02, a price-to-earnings-growth ratio of 2.80 and a beta of 0.77. The stock has a 50-day simple moving average of $195.74 and a 200-day simple moving average of $206.85. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. On average, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is currently 24.85%.
Wall Street Analysts Forecast Growth
DHR has been the topic of several research reports. TD Cowen raised their price target on shares of Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Wells Fargo & Company decreased their price target on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. UBS Group decreased their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Bank of America decreased their price target on shares of Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Finally, Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $248.00.
View Our Latest Stock Report on DHR
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading

Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report